GD2-GD3 Bispecific Vaccine
Neuroblastoma
Early ClinicalActive
Key Facts
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, founded in 2015 and headquartered in New York, is a commercial-stage biotech company specializing in antibody-based oncology treatments. Its lead asset, DANYELZA, is an FDA-approved therapy for relapsed/refractory high-risk neuroblastoma, representing a significant advancement for a rare pediatric cancer. The company is now part of SERB Pharmaceuticals, which provides strategic and financial backing for its pipeline development. Y-mAbs continues to leverage its expertise in radioimmunotherapy and antibody engineering to address unmet needs in solid tumors.
View full company profileTherapeutic Areas
Other Neuroblastoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Neuroblastoma Risk Stratification | Quibim | Research |
| VNX-201 | Vironexis Biotherapeutics | Preclinical |
| DANYELZA® (naxitamab) | SERB Pharmaceuticals | Approved |
| Dinutuximab (OP-08/Unituxin®) | Ohara Pharmaceutical | Approved |
| GAIA-102 (fulamleucel) (iv + pretreatment) | GAIA BioMedicine | Early clinical trial |